Sandra C. Raymond, President and CEO of the Lupus Foundation of America joined U.S. Representative Robin Kelly (D-IL), of Illinois’ 2nd Congressional District and Chair of the Congressional Black Caucus (CBC) Health Braintrust at an event Friday, September 18 to release official Congressional analysis of the state of African…
The American College of Rheumatology’s (ACR) The Lupus Initiative (TLI) has awarded a one-year, $500,000 grant from the Office of Minority Health (OMH) to expand its established, national education program with development of an evidence-based program model aimed at improved health outcomes for people with lupus living…
Janus Biotherapeutics (Janus), a Boston, Massachusetts based autoimmunity therapeutics company dedicated to development of novel, orally available compounds for treating autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren’s syndrome, psoriasis, and scleroderma, have announced their entry into a collaboration with multinational pharma firm Roche…
Sandra C. Raymond, President and CEO of the Lupus Foundation of America recently participated in a briefing for U.S. Senate staff discussing off-label uses of medications for treating lupus and the importance of physicians having vital information about the impact these off-label medications may have on lupus patients. Lupus…
The Senate Appropriations Committee’s 2016 spending bill passed June 25 includes some good news for people with lupus. Sandra C. Raymond, President & CEO of the Lupus Foundation of America notes in a statement that the bill provides support for funding of valuable lupus research and education programs, and…
Raanana, Israel based XTL Biopharmaceuticals Ltd. (XTL) has announced that following evaluation of market opportunity for its pipeline products its decision to focus efforts and expenditures exclusively on two core assets: hCDR1 for treatment of SLE/lupus and rHuEPO for “no-option” multiple myeloma patients. XTL, whose shares are traded on the…
Paris, France based Neovacs, a biotech firm specializing in active immunotherapies for treating autoimmune diseases, has announced establishment of a wholly-owned U.S. subsidiary, Neovacs, Inc., which is headquartered in Boston and incorporated in Delaware. Creation of a U.S. subsidiary is an important strategic step for Neovacs in extending clinical initiatives…
The New York and Chicago based non-profit Lupus Research Institute (LRI) Coalition, along with lupus patients nationwide are hopeful that the year-end Congressional Fiscal 2015 Consolidated and Further Continuing Appropriations Act will authorize support for several lupus research and professional education programs after the organization’s year-log advocacy. An…
According to research recently published in the American Society for Microbiology’s journal Applied and Environmental Microbiology, Lactobacillus — a probiotic (beneficial bacteria) species commonly found in yogurt cultures — has been discovered to correlate in the gut of laboratory mouse models, with symptom mitigation in the autoimmune disorder systemic…